CBDMD INC (YCBD)
AMEXHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$0.41-3.10%
Close 2026-11-04 · 1-day change
AMEXHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
QuarterlyIQ Insights · YCBD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 35.1% |
Growth built into the price is above our model estimate.
The price assumes 125.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 8 industry peers
YCBD — capital allocation
Dated 2026-11-04
below (the “Assumed Debt”), with the balance of the Assignors’ obligations to the Secured Creditor forgiven; (b) the issuance to the Secured Creditor of 2,229,805 shares of the Company’s common stock, par value $0.001 per share, valued at $1.00 per share, which equaled 19.9% of the outstanding shares of the Company’s common stock as of the execution date of the APA (the “Common Stock Consideration”); (c) the Additional Target Percentage Shares (as defined below); and (d) the assumption of the…
Why it matters: The deal adds four brands and is tied to about $30 million in combined trailing revenue. Court approval and closing remain open conditions.
Watch forA court approves the asset sale and cbdMD reports that the deal has closed.
Also watch forThe court rejects the sale, a closing condition fails, or cbdMD reports the deal is terminated.
Why it matters: The company has new financial obligations, a planned acquisition, and a long lease. Its next report can show how these demands affect cash and funding.
Worry ifThe next filing reports higher cash use, added debt, or new funding needs tied to the deal or lease.
Less concerning ifThe next filing shows the deal closed without new debt or funding needs, and cash use does not rise.
Why it matters: Current signals flag weak revenue and loss-making results. The December report can show whether the business is improving or still losing money.
Worry ifThe December 18 report shows another loss and higher cash use than the prior report.
Less concerning ifThe report shows a smaller loss or a profit, with lower cash use than the prior report.
Why it matters: The stated $30 million is an unaudited past-revenue figure, not a forecast. Results can show if the added sales cover deal and integration costs.
Watch forThe first report after closing shows sales from acquired brands. It also shows a positive contribution after deal and integration costs.
Also watch forThe first report after closing shows acquired-brand sales below plan. Or, costs leave the deal with a negative contribution.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$273 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $1,022 loss on $10,000 · 10.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,467 loss on $10,000 · 84.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.